Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer

被引:37
作者
Coutanceau, Emmanuelle
Legras, Pierre
Marsollier, Laurent
Reysset, Gilles
Cole, Stewart T.
Demangel, Caroline
机构
[1] Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France
[2] CHU Angers, Anim Hosp Univ, Angers, France
关键词
Mycobacterium ulcerans; Buruli ulcer; Hsp65; vaccination;
D O I
10.1016/j.micinf.2006.03.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Buruli ulcer, a disease caused by Mycobacterium ulcerans, is emerging as an increasingly important cause of morbidity throughout the world, for which surgery is the only efficient treatment to date. The aim of this work was to identify potential vaccine candidates in an experimental model of mouse infection. In BALB/c mice infected with M. ulcerans subcutaneously, Hsp65 appeared to be an immunodominant antigen eliciting both Immoral and cellular responses. However, vaccination of mice with a DNA vector encoding Mycobacterium leprae Hsp65 only poorly limited the progression of M. ulcerans infection. In contrast, a substantial degree of protection was conferred by subcutaneous vaccination with BCG, suggesting that BCG antigens that are conserved in M. ulcerans, such as TB 10.4, the 19 kDa antigen, PstS3 and Hsp70, may be interesting to consider as subunit vaccines in future prospects. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:2075 / 2081
页数:7
相关论文
共 19 条
[11]  
Kamath AT, 1999, INFECT IMMUN, V67, P1702
[12]   Therapy of tuberculosis in mice by DNA vaccination [J].
Lowrie, DB ;
Tascon, RE ;
Bonato, VLD ;
Lima, VMF ;
Faccioli, LH ;
Stavropoulos, E ;
Colston, MJ ;
Hewinson, RG ;
Moelling, K ;
Silva, CL .
NATURE, 1999, 400 (6741) :269-271
[13]   Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice [J].
Oliveira, MS ;
Fraga, AG ;
Torrado, E ;
Castro, AG ;
Pereira, JP ;
Longatto, A ;
Milanezi, F ;
Schmitt, FC ;
Meyers, WM ;
Portaels, F ;
Silva, MT ;
Pedrosa, J .
INFECTION AND IMMUNITY, 2005, 73 (10) :6299-6310
[14]   Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer) [J].
Portaels, F ;
Aguiar, J ;
Debacker, M ;
Steunou, C ;
Zinsou, C ;
Guédénon, A ;
Meyers, WM .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002, 9 (06) :1389-1391
[15]   Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease [J].
Prévot, G ;
Bourreau, E ;
Pascalis, H ;
Pradinaud, R ;
Tanghe, A ;
Huygen, K ;
Launois, P .
INFECTION AND IMMUNITY, 2004, 72 (02) :958-965
[16]   The potential use of heat-shock proteins to vaccinate against mycobacterial infections [J].
Silva, CL .
MICROBES AND INFECTION, 1999, 1 (06) :429-435
[17]   PROTECTIVE EFFECT OF BCG AGAINST MYCOBACTERIUM-ULCERANS DISEASE - CONTROLLED TRIAL IN AN ENDEMIC AREA OF UGANDA [J].
SMITH, PG ;
REVILL, WDL ;
LUKWAGO, E ;
RYKUSHIN, YP .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1976, 70 (5-6) :449-457
[18]   Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer [J].
Tanghe, A ;
Content, J ;
Van Vooren, JP ;
Portaels, F ;
Huygen, K .
INFECTION AND IMMUNITY, 2001, 69 (09) :5403-5411
[19]   Vaccination against tuberculosis by DNA injection [J].
Tascon, RE ;
Colston, MJ ;
Ragno, S ;
Stavropoulos, E ;
Gregory, D ;
Lowrie, DB .
NATURE MEDICINE, 1996, 2 (08) :888-892